{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+%28With+or+Without+Metastasis%29&page=5", "query": { "condition": "Cancer (With or Without Metastasis)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 577, "total_pages": 58, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+%28With+or+Without+Metastasis%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+%28With+or+Without+Metastasis%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T22:46:44.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004899", "title": "Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2012-06-12", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004899" }, { "nct_id": "NCT03508570", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Peritoneal Neoplasm", "Malignant Retroperitoneal Neoplasm", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Fallopian Tube Carcinoma", "Metastatic Malignant Female Reproductive System Neoplasm", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Peritoneal Carcinomatosis", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Malignant Female Reproductive System Neoplasm", "Platinum-Refractory Ovarian Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Malignant Female Reproductive System Neoplasm", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2018-09-21", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03508570" }, { "nct_id": "NCT03120624", "title": "VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Endometrial Carcinoma", "Recurrent Endometrial Adenocarcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Mixed Cell Adenocarcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Stage IV Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorine F 18 Tetrafluoroborate", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Technetium Tc-99m Sodium Pertechnetate", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2017-09-15", "completion_date": "2028-01-01", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03120624" }, { "nct_id": "NCT07549412", "title": "A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Precemtabart tocentecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine/Tipiracil (FTD-TPI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1020, "start_date": "2026-05-06", "completion_date": "2029-10-16", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 19, "location_summary": "Lone Tree, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 16 more", "locations": [ { "city": "Lone Tree", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07549412" }, { "nct_id": "NCT00003444", "title": "Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 167, "start_date": "1999-03-29", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 23, "location_summary": "Atlanta, Georgia • Decatur, Georgia • Chicago, Illinois + 15 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003444" }, { "nct_id": "NCT00098826", "title": "SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Undifferentiated Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Acute Promyelocytic Leukemia (M3)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "ispinesib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-11", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098826" }, { "nct_id": "NCT00045435", "title": "Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 17, "start_date": "2002-04", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 2, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045435" }, { "nct_id": "NCT00003584", "title": "Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "estramustine phosphate sodium", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 35, "start_date": "1998-07", "completion_date": "2000-12", "has_results": false, "last_update_posted_date": "2016-05-12", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003584" }, { "nct_id": "NCT05677490", "title": "mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastric Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 382, "start_date": "2023-01-31", "completion_date": "2028-11-08", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 791, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 508 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05677490" }, { "nct_id": "NCT01256385", "title": "Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Verrucous Carcinoma", "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary", "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Recurrent Oral Cavity Verrucous Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Recurrent Salivary Gland Carcinoma", "Salivary Gland Squamous Cell Carcinoma", "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary", "Stage IV Hypopharyngeal Squamous Cell Carcinoma", "Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVA Laryngeal Squamous Cell Carcinoma", "Stage IVA Laryngeal Verrucous Carcinoma", "Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVA Major Salivary Gland Carcinoma", "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVA Oral Cavity Verrucous Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Stage IVB Laryngeal Squamous Cell Carcinoma", "Stage IVB Laryngeal Verrucous Carcinoma", "Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVB Major Salivary Gland Carcinoma", "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVB Oral Cavity Verrucous Carcinoma", "Stage IVB Oropharyngeal Squamous Cell Carcinoma", "Stage IVC Laryngeal Squamous Cell Carcinoma", "Stage IVC Laryngeal Verrucous Carcinoma", "Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVC Major Salivary Gland Carcinoma", "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVC Oral Cavity Verrucous Carcinoma", "Stage IVC Oropharyngeal Squamous Cell Carcinoma", "Tongue Carcinoma" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2010-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-03-27", "last_synced_at": "2026-10-06T22:46:44.337Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01256385" } ] }